Skip to main content
Equibles

Geoffrey Parker

CFO

Allogene Therapeutics, Inc. (ALLO)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Geoffrey Parker

Geoffrey Parker is recorded as CFO at Allogene Therapeutics, Inc. (ALLO). Allogene Therapeutics, Inc. reported in an 8-K filed September 2, 2026 that Geoffrey Parker retired as Executive Vice President and Chief Financial Officer, effective November 6, 2026. Allogene Therapeutics, Inc. reported in an 8-K filed October 16, 2023 that Geoffrey Parker was appointed Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective October 16, 2023. Geoffrey Parker has spoken on 1 earnings call across 1 company, most recently for Allogene Therapeutics, Inc. on May 13, 2026.

“On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.”
Allogene Therapeutics, Inc. Form 8-K, filed September 2, 2026 · Read the filing
“The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023.”
Allogene Therapeutics, Inc. Form 8-K, filed October 16, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Allogene Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.